Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Alert-based monitoring of patient-reported symptoms significantly improves fatigue and quality of life and prolongs survival ...

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

New York, United States - September 05, 2024 Demonstrators protest against Gilead Pharmaceuticals in midtown Manhattan.

● Marion Harding wrestler Sidney Barkley won her weight class at Urbana's Battle of the Hill Tournament. ● Cardington ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...

After a median follow-up of 9.6 years, irradiated patients had a 10-year overall survival (OS) of 81.4% versus 82% for those ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...